Literature DB >> 20431562

Inhaled aztreonam.

Brian P O'Sullivan1, Uma Yasothan, Peter Kirkpatrick.   

Abstract

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20431562     DOI： 10.1038/nrd3170

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  10 in total

1.  Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.

Authors:  Ronald L Gibson; George Z Retsch-Bogart; Christopher Oermann; Carlos Milla; Joseph Pilewski; Cori Daines; Richard Ahrens; Kevin Leon; Morty Cohen; Sharon McNamara; Tracy L Callahan; Richard Markus; Jane L Burns
Journal:  Pediatr Pulmonol       Date:  2006-07

2.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

3.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

4.  A pipeline of therapies for cystic fibrosis.

Authors:  Melissa A Ashlock; Robert J Beall; Nicole M Hamblett; Michael W Konstan; Christopher M Penland; Bonnie W Ramsey; Jill M Van Dalfsen; Diana R Wetmore; Preston W Campbell
Journal:  Semin Respir Crit Care Med       Date:  2009-09-16       Impact factor: 3.119

Review 5.  Cystic fibrosis.

Authors:  Brian P O'Sullivan; Steven D Freedman
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

6.  Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.

Authors:  T Jensen; S S Pedersen; S Garne; C Heilmann; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

Review 7.  Aerosol antibiotics in cystic fibrosis.

Authors:  David E Geller
Journal:  Respir Care       Date:  2009-05       Impact factor: 2.258

8.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Authors:  George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Christopher M Oermann; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

Review 9.  Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator.

Authors:  Beth A Smith; Beatrice L Wood
Journal:  Curr Opin Pediatr       Date:  2007-10       Impact factor: 2.856

10.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405
  10 in total
  5 in total

1.  Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.

Authors:  Karen Smith; Laura Martin; Angela Rinaldi; Ranjith Rajendran; Gordon Ramage; Daniel Walker
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

2.  Genomic Analysis Identifies Novel Pseudomonas aeruginosa Resistance Genes under Selection during Inhaled Aztreonam Therapy In Vivo.

Authors:  Kathryn McLean; Duankun Lee; Elizabeth A Holmes; Kelsi Penewit; Adam Waalkes; Mingxin Ren; Samuel A Lee; Joseph Gasper; Colin Manoil; Stephen J Salipante
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa.

Authors:  Peter Jorth; Kathryn McLean; Anina Ratjen; Patrick R Secor; Gilbert E Bautista; Sumedha Ravishankar; Amir Rezayat; Jayanthi Garudathri; Joe J Harrison; Rachel A Harwood; Kelsi Penewit; Adam Waalkes; Pradeep K Singh; Stephen J Salipante
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867

4.  A MexR Mutation Which Confers Aztreonam Resistance to Pseudomonas aeruginosa.

Authors:  Zhenzhen Ma; Congjuan Xu; Xinxin Zhang; Dan Wang; Xiaolei Pan; Huimin Liu; Guangbo Zhu; Fang Bai; Zhihui Cheng; Weihui Wu; Yongxin Jin
Journal:  Front Microbiol       Date:  2021-06-24       Impact factor: 5.640

5.  Systems-level analysis of NalD mutation, a recurrent driver of rapid drug resistance in acute Pseudomonas aeruginosa infection.

Authors:  Jinyuan Yan; Henri Estanbouli; Chen Liao; Wook Kim; Jonathan M Monk; Rayees Rahman; Mini Kamboj; Bernhard O Palsson; Weigang Qiu; Joao B Xavier
Journal:  PLoS Comput Biol       Date:  2019-12-20       Impact factor: 4.475
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.